In this episode, host Tylah Tully looks at Entropy Neurodynamics (ASX:ENP) who has received encouraging first results from a ...
A psychedelic compound found in “magic mushrooms” could help Australians with binge-eating disorders control the urge for ...
Stockhead on MSN
Entropy’s psilocybin therapy shows rapid and sustained reduction of binge eating in 100pc of patients
Entropy Neurodynamics has received positive Phase 2a results for its psilocybin-based therapy in patients with Binge Eating ...
Our mission is to support our patients with mental or neurological disorders from the initial diagnostic to the end of the intervention, offering them state of the art technology to evaluate and treat ...
Second infusion administered following clearance from Drug and Safety Monitoring Board after safety review of first infusion Patient will now undergo supportive psychotherapy, ahead of post-treatment ...
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback